Adrenomed AG. (5/6/19). "Press Release: Adrenomed AG Takes Part in Three Upcoming Conferences". Hennigsdorf.

	Region	Barcelona
	Country	Spain (España)
	Organisation	Adrenomed AG
	Organisation 2	BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization)
	Product	BioEquity Europe 2019 Barcelona
	Product 2	BIO 2019 Philadelphia (BIO International Convention)
	Index term	Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona
	Index term 2	Adrenomed–BIO (US): partnering conference, 201906 supply service Adrenomed presents at BIO International Convention
	Person	Hein, Frauke (Bico 202206– CEO of Scienion before MLDx GmbH + Adrenomed + BRAHMS + Brandenburg)
	Person 2	Bauer, Eva (MC Services 201811)

Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at the following events:

Swiss Biotech Day 2019 and Annual General Assembly of the Swiss Biotech Association
May 07, 2019, Congress Center, Basel, Switzerland
https://swissbiotechday.ch/home/

20th Annual Bio€quity Europe
May 20 – 21, 2019, Crowne Plaza Barcelona Fira Center, Barcelona, Spain
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a company presentation on May 20, 16:30 CET, room Rossini 2.
https://www.biocentury.com/conferences/bio€quity-europe-2019

BIO International Convention 2019
June 3 – 6, 2019, Pennsylvania Convention Center, Philadelphia (PA), USA
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will represent the company and give a presentation.
https://convention.bio.org/

About Adrenomed

Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.

Contact

Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu

Record changed: 2023-06-05